PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 04, 2023
Share
PharmaEngine, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 166.07 million compared to TWD 166.9 million a year ago. Net income was TWD 75.12 million compared to TWD 80.67 million a year ago. Basic earnings per share from continuing operations was TWD 0.52 compared to TWD 0.56 a year ago. Diluted earnings per share from continuing operations was TWD 0.52 compared to TWD 0.56 a year ago.
For the six months, sales was TWD 334.4 million compared to TWD 341.03 million a year ago. Net income was TWD 156.5 million compared to TWD 177.7 million a year ago. Basic earnings per share from continuing operations was TWD 1.09 compared to TWD 1.24 a year ago. Diluted earnings per share from continuing operations was TWD 1.09 compared to TWD 1.24 a year ago.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,